Skip to content

Preemptive Effects of Preoperative Single Infusion of Ademetionine 1,4-Butanedisulfonate for Injection on Perioperative Neurocognitive Disorders (PND) in Patients undergoing non-Cardiac Surgery

Preemptive Effects of Preoperative Single Infusion of Ademetionine 1,4-Butanedisulfonate for Injection on Perioperative Neurocognitive Disorders in Patients undergoing non-Cardiac Surgery: A Single-Center, Prospective, Randomized, Double-blinded, Controlled, Explorative Clinical Trial - SMART

Status
Active, not recruiting
Phases
Early Phase 1
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2300076525
Enrollment
Unknown
Registered
2023-10-11
Start date
2023-10-11
Completion date
Unknown
Last updated
2023-11-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Perioperative Neurocognitive Disorders

Interventions

Treatment Group:Continuous and slow intravenous infusion of Ganfu'neng 500 mg 1 hour before operation (0.9% normal saline 250 ml dilution, infusion rate: 250 ml / h)
Placebo Group:Continuous slow intravenous infusion of equal volume of water 1 hour before operation (0.9% saline 250 ml, infusion rate: 250ml / h)

Sponsors

Department of Anesthesiology and Perioperative medicine, Shanghai Fourth People’s Hospital, School of Medicine, Tongji University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
65 Years to 110 Years

Inclusion criteria

Inclusion criteria: 1) Age over 65 years old; 2) Scheduled for Total Knee Replacement, Total Hip Replacement, or hip fracture under general anesthesia. Estimated anesthesia and surgery time over 1 hour; 3) Signed written informed consent obtained.

Exclusion criteria

Exclusion criteria: 1) Disease of the central nervous system, including all kinds of dementia, and depression; 2) MMSE score lower than 24; 3) Education time 177 umol/L); 10) Alcohol or drug addicted, had drank more than 5u of liqueur for the past 3 months. One unit equals 10ml or 8g pure alcohol; 11) Second surgery of the same elected patients, no matter the cause of surgery.

Design outcomes

Primary

MeasureTime frame
Incidence of PND one day before discharge (or 7 days after operation);

Secondary

MeasureTime frame
Anxiety / depression state of patients 7 days after operation / before discharge;Activities of daily living of patients with telephone follow-up 3 months after operation;The levels of serum homocysteine (Hcy), ubiquitin carboxyl terminal hydrolase 25 (USP25) and free myeloid differentiation factor 2 (MD2) will be measured immediately before operation (before administration), immediately after operation and 24 hours after operation (morning blood on the first day after operation);Postoperative hospital stay;Incidence of postoperative complications;

Countries

China

Contacts

Public ContactXiong Lize

Shanghai Fourth People’s Hospital, School of Medicine, Tongji University

mzkxlz@126.com+86 21 5666 0851

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026